Monash Ivf Group Ltd
Monash IVF Group Limited engages in the provision of assisted reproductive and specialist women imaging services in Australia and Malaysia. It offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. It also provides tertiary level prenatal diagnostic, and IVF treatment services. Monash IVF Group Limited was incorporated in 2014 and is headquartered in Richmond, Au… Read more
Monash Ivf Group Ltd (MVF) - Net Assets
Latest net assets as of December 2025: AU$257.95 Million AUD
Based on the latest financial reports, Monash Ivf Group Ltd (MVF) has net assets worth AU$257.95 Million AUD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$510.21 Million) and total liabilities (AU$252.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$257.95 Million |
| % of Total Assets | 50.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | -6.71% |
| 10-Year Change | 61.69% |
| Growth Volatility | 13.4 |
Monash Ivf Group Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Monash Ivf Group Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Monash Ivf Group Ltd (2013–2025)
The table below shows the annual net assets of Monash Ivf Group Ltd from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$250.42 Million | +1.52% |
| 2024-06-30 | AU$246.66 Million | -10.33% |
| 2023-06-30 | AU$275.07 Million | +1.92% |
| 2022-06-30 | AU$269.89 Million | +0.54% |
| 2021-06-30 | AU$268.44 Million | +6.47% |
| 2020-06-30 | AU$252.12 Million | +45.37% |
| 2019-06-30 | AU$173.43 Million | +3.94% |
| 2018-06-30 | AU$166.86 Million | +2.04% |
| 2017-06-30 | AU$163.52 Million | +5.58% |
| 2016-06-30 | AU$154.88 Million | +7.53% |
| 2015-06-30 | AU$144.03 Million | +15.39% |
| 2014-06-30 | AU$124.82 Million | +366.03% |
| 2013-06-30 | AU$-46.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Monash Ivf Group Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5404500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$506.79 Million | 205.78% |
| Other Comprehensive Income | AU$-143.37 Million | -58.22% |
| Total Equity | AU$246.28 Million | 100.00% |
Monash Ivf Group Ltd Competitors by Market Cap
The table below lists competitors of Monash Ivf Group Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Edel SE & Co. KGaA
F:EDL
|
$116.85 Million |
|
CHT Security Co., Ltd.
TW:7765
|
$116.86 Million |
|
Hanyang Sec
KO:001750
|
$116.96 Million |
|
Gold Resource Corporation
NYSE MKT:GORO
|
$116.96 Million |
|
63 moons technologies limited
NSE:63MOONS
|
$116.76 Million |
|
DB INC
KO:012030
|
$116.75 Million |
|
Navneet Education Limited
NSE:NAVNETEDUL
|
$116.74 Million |
|
Organización Cultiba S.A.B. de C.V
MX:CULTIBAB
|
$116.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Monash Ivf Group Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 241,905,000 to 246,275,000, a change of 4,370,000 (1.8%).
- Net income of 25,008,000 contributed positively to equity growth.
- Dividend payments of 19,871,000 reduced retained earnings.
- Other comprehensive income decreased equity by 41,223,999.
- Other factors increased equity by 40,456,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$25.01 Million | +10.15% |
| Dividends Paid | AU$19.87 Million | -8.07% |
| Other Comprehensive Income | AU$-41.22 Million | -16.74% |
| Other Changes | AU$40.46 Million | +16.43% |
| Total Change | AU$- | 1.81% |
Book Value vs Market Value Analysis
This analysis compares Monash Ivf Group Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-06-30 | AU$-0.28 | AU$0.64 | x |
| 2014-06-30 | AU$0.38 | AU$0.64 | x |
| 2015-06-30 | AU$0.62 | AU$0.64 | x |
| 2016-06-30 | AU$0.47 | AU$0.64 | x |
| 2017-06-30 | AU$0.69 | AU$0.64 | x |
| 2018-06-30 | AU$0.71 | AU$0.64 | x |
| 2019-06-30 | AU$0.69 | AU$0.64 | x |
| 2020-06-30 | AU$0.77 | AU$0.64 | x |
| 2021-06-30 | AU$0.68 | AU$0.64 | x |
| 2022-06-30 | AU$0.68 | AU$0.64 | x |
| 2023-06-30 | AU$0.70 | AU$0.64 | x |
| 2024-06-30 | AU$0.62 | AU$0.64 | x |
| 2025-06-30 | AU$0.63 | AU$0.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Monash Ivf Group Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.15%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.20%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 2.00x
- Recent ROE (10.15%) is above the historical average (8.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -15.38% | 0.36x | 0.00x | AU$-13.48 Million |
| 2014 | 2.07% | 2.26% | 0.46x | 1.97x | AU$-9.90 Million |
| 2015 | 14.84% | 17.10% | 0.44x | 1.97x | AU$6.97 Million |
| 2016 | 18.58% | 18.38% | 0.54x | 1.86x | AU$13.29 Million |
| 2017 | 18.11% | 19.09% | 0.54x | 1.76x | AU$13.27 Million |
| 2018 | 12.82% | 14.18% | 0.52x | 1.74x | AU$4.69 Million |
| 2019 | 11.46% | 13.06% | 0.52x | 1.67x | AU$2.53 Million |
| 2020 | 4.69% | 8.06% | 0.41x | 1.42x | AU$-13.25 Million |
| 2021 | 9.45% | 13.70% | 0.52x | 1.34x | AU$-1.47 Million |
| 2022 | 6.87% | 9.57% | 0.50x | 1.44x | AU$-8.39 Million |
| 2023 | 7.99% | 10.22% | 0.51x | 1.54x | AU$-5.48 Million |
| 2024 | -2.70% | -2.56% | 0.50x | 2.10x | AU$-30.72 Million |
| 2025 | 10.15% | 9.20% | 0.55x | 2.00x | AU$380.50K |
Industry Comparison
This section compares Monash Ivf Group Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $147,423,507
- Average return on equity (ROE) among peers: -32.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Monash Ivf Group Ltd (MVF) | AU$257.95 Million | 0.00% | 0.98x | $116.82 Million |
| Australian Clinical Labs Ltd (ACL) | $68.99 Million | 59.80% | 4.31x | $220.73 Million |
| Bcal Diagnostics Ltd (BDX) | $6.22 Million | -116.40% | 0.59x | $10.55 Million |
| Capitol Health Ltd (CAJ) | $144.04 Million | 0.60% | 0.82x | $222.66 Million |
| Cryosite Ltd (CTE) | $1.45 Million | 126.98% | 12.60x | $4.84 Million |
| Genetic Signatures Ltd (GSS) | $16.18 Million | -10.68% | 0.02x | $7.79 Million |
| Healius Ltd (HLS) | $1.04 Billion | -62.05% | 1.87x | $208.81 Million |
| Inoviq Ltd (IIQ) | $2.83 Million | -115.42% | 0.16x | $25.42 Million |
| Microba Life Sciences Ltd (MAP) | $32.49 Million | -45.98% | 0.46x | $10.42 Million |
| Pacific Edge Ltd (PEB) | $13.91 Million | -128.81% | 0.19x | $81.52 Million |